How much alcohol is in ketamine's antidepressant action?
Life Sciences January 1, 2017 DOI: 10.1016/j.lfs.2016.11.003 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Intervention | Ketamine |
| Topics | Addiction Ketamine Esketamine |
| Keywords | Antidepressant response Dopamine Ethanol Glutamate |
| Key points | Argues that ketamine's rapid antidepressant response in treatment-resistant depression is usually short-lived (up to seven days), and that existing clinical studies and follow-ups are too short to establish ketamine's addictive and neurotoxic liability after repeated or prolonged administration. Proposes that ketamine and alcohol share striking similarities in glutamatergic and dopaminergic modulation in cortico-limbic brain areas involved in learning, reward, and mood regulation, and in immunoinhibitory effects, which may mediate both antidepressant response and addiction. |
Abstract
Ketamine is approved to start and maintain anaesthesia or analgesia. Ketamine is also known to be neurotoxic and an old drug of abuse. Numerous studies have proven a rapid and strong antidepressant response (AR) following parenteral sub-anaesthetic ketamine doses when applied the first time to patients with treatment resistant unipolar or bipolar major depression. This rapid and robust AR is encouraging, though short-lived (usually up to seven days). There is growing evidence that repeated und escalating ketamine administrations exert longer-lasting AR than single infusions. Yet, the clinical studies and follow-ups are still too short-lasting to get useful information about ketamine's liability to be addictive and neurotoxic after repeated or even prolonged administrations to severely depressed patients. In this vein, it could be worth to have a look at a couple of pharmacological features that ketamine shares with alcohol being presented here. In essence, there are striking similarities between ketamine and alcohol particularly in terms of modulating glutamatergic and dopaminergic signaling in cortico-limbic brain areas involved in learning, reward and mood regulation, thereby, probably mediating both, AR as well as the development of addiction. Moreover, moderate amounts of both drugs have comparable immunoinhibitory effects hypothesized to be involved in AR, too.
Citations in the library
Cites 13
- Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings) CNS Neuroscience & Therapeutics April 10, 2013
- A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression American Journal of Psychiatry April 8, 2016
- Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics Annual Review of Medicine October 23, 2014
- The use of ketamine as an antidepressant: a systematic review and meta‐analysis Human Psychopharmacology: Clinical and Experimental April 7, 2015
- To use or not to use: an update on licit and illicit ketamine use Substance Abuse and Rehabilitation March 1, 2011
and 8 more in the library